- Published at
- by manilatimes.net
positive
positive
News for Enzo Biochem, Inc. (ENZ)
- Published at
- by gurufocus.com
positivepositiveOTC Markets Group Welcomes Enzo Biochem, Inc. to OTCQX | OTCM Stock News
Enzo Biochem (ENZB) transitions from NYSE to OTCQX Best Market. Trading commenced on April 21, 2025, under the symbol 'ENZB'. OTCQX offers cost-effec- Published at
- by gurufocus.com
positivepositiveOTC Markets Group Welcomes Enzo Biochem, Inc. to OTCQX
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international sec- Published at
- by manilatimes.net
positivepositive- Published at
- by financialpost.com
positivepositiveOTC Markets Group Welcomes Enzo Biochem, Inc. to OTCQX
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) —- Published at
- by zacks.com
mixedmixedTop Research Reports for AbbVie, TJX & Charles Schwab
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), The TJX Companies, Inc. (TJX) and The Charles Schwab Corporation (SCHW), as well as two micro-cap stocks, Enzo Biochem, Inc. (ENZ) and CVD Equipment Corporation (CVV).- Published at
- by benzinga.com
mixedmixedWhy Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - argenx (NASDAQ:ARGX), AlTi Global (NASDAQ:ALTI)
Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-i...- Published at
- by gurufocus.com
positivepositiveEnzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (: ENZ) (”Enzo” or the ”Company”) today announced its intention to voluntari- Published at
- by gurufocus.com
mixedmixedTETRA TECHNOLOGIES, INC. ANNOUNCES INTENT TO CONTINUE BOARD REFRESHMENT AT 2025 ANNUAL MEETING OF SHAREHOLDERS
PR NewswireTHE WOODLANDS, Texas, March 25, 2025 Also Discloses Receipt of Nomination Notice from Shareholder Brad RadoffNotes Shareholders Are Not Required- Published at
- by gurufocus.com
mixedmixedThe Radoff-Torok Group Nominates Four Highly Qualified, Independent Director Candidates for Election to the TETRA Technologies Board of Directors
PR NewswireHOUSTON, March 24, 2025 Sends Letter to TTI Board Highlighting Decades-Long Underperformance, Lack of Strategy, Poor Corporate Governance, Faile- Published at
- by gurufocus.com
positivepositiveEnzo Biochem Inc (ENZ) Reports Q2 Fiscal 2025 Revenue of $7.3 Million and Significant Gross Margin Improvement
Enzo Biochem Inc (ENZ) released its 8-K filing on March 18, 2025, detailing the financial results for the fiscal second quarter ended January 31, 2025. The bios- Published at
- by gurufocus.com
neutralneutralEnzo Biochem Reports Second Quarter Fiscal Year 2025 Results
FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (: ENZ) (”Enzo” or the ”Company”) today announced financial results for the f- Published at
- by manilatimes.net
neutralneutralEnzo Biochem Reports Second Quarter Fiscal Year 2025 Results
**media[568912]**- Published at
- by gurufocus.com
positivepositiveEnzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules
FARMINGDALE, N.Y, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (: ENZ) (”Enzo” or the ”Company”) today announced that it was notified by the N- Published at
- by seekingalpha.com
neutralneutralEnzo Biochem receives NYSE non-compliance notice
Enzo Biochem notified by NYSE for non-compliance with listing rules.- Published at
- by manilatimes.net
neutralneutral- Published at
- by gurufocus.com
positivepositiveEnzo Biochem (ENZ) Stock Surges 5.19% Amid Market Activity
Enzo Biochem Inc. (ENZ) experienced a significant stock movement with a 5.19% increase. The stock is currently valued at $0.750 per share, with a trading volume- Published at
- by manilatimes.net
neutralneutral- Published at
- by seekingalpha.com
neutralneutralEnzo Biochem Non-GAAP EPS of -$0.05, revenue of $6.21M (NYSE:ENZ)
Enzo Biochem (ENZ) reports first quarter fiscal year 2025 results with non-GAAP EPS of -$0.05 and revenue of $6.21M, down 20.5% year-over-year.- Published at
- by zacks.com
neutralneutralThe Zacks Analyst Blog Highlights Amgen, Eaton, Sony, iMage and Enzo Biochem
Amgen, Eaton, Sony, iMage and Enzo Biochem are included in this Analyst Blog.